L3VLUP
ProSign in

SNDX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SNDXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SNDX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSNDXVRTX
Q3 20201 holders, $4.1m31 holders, $21.9bn
Q4 20207 holders, $64m30 holders, $18.4bn
Q1 20212 holders, $34m31 holders, $15.4bn
Q2 20211 holders, $3.6m30 holders, $12.7bn
Q3 20211 holders, $11m35 holders, $10.1bn
Q4 20211 holders, $6.8m28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 20222 holders, $20m22 holders, $18.4bn
Q4 20223 holders, $235m28 holders, $18.4bn
Q1 20232 holders, $159m26 holders, $21.4bn
Q2 20235 holders, $209m27 holders, $24.7bn
Q3 20234 holders, $160m33 holders, $24.3bn
Q4 20237 holders, $322m32 holders, $28.6bn
Q1 20249 holders, $362m31 holders, $29.8bn
Q2 20248 holders, $322m29 holders, $33.4bn
Q3 20246 holders, $117m27 holders, $33.5bn
Q4 20243 holders, $50m26 holders, $28.5bn
Q1 20254 holders, $76m21 holders, $35.4bn
Q2 20253 holders, $38m21 holders, $32.3bn
Q3 20253 holders, $89m22 holders, $25.9bn
Q4 20256 holders, $165m26 holders, $31.8bn
Q1 20266 holders, $96m25 holders, $31.8bn
Q2 20263 holders, $36m26 holders, $34.6bn
SNDX

Syndax Pharmaceuticals Inc

Holders
8
Reported value
$322m
Buyers
5
Sellers
2

Breadth +3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SNDX (4)

ExodusPoint Capital Management LP, Farallon Capital Management LLC, Point72 Asset Management LP, Woodline Partners LP

Only VRTX (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →